



**2026 Commercial Specialty Pharmacy Prior Authorization Codes  
Effective 1/1/2026  
(Updated October 2025)**

**This list includes procedure code changes for Medical Benefit Specialty Pharmacy that may require benefit prior authorization through Blue Cross Blue Shield of Montana effective Jan. 1, 2025.**

**Use this document to view details for a procedure code, including:**

- 1) Drug Product Name - Brand (generic)**
- 2) Reason for prior authorization where medical necessity review is required for both therapy and place of infusion (Infusion Site of Care) or for therapy only (Provider Administered Drug Therapy) and/or for Medical Oncology & Supportive Care**
- 3) Effective date for when prior authorization was implemented at BCBSMT (provider administered drug therapy or infusion site of care) or Carelon Medical Benefits Management (requests for oncology drugs that are supported by an oncology diagnosis).**

**Utilization Management Process**

**This file is a searchable PDF.  
Press "CTRL" and "F" keys at the same time to bring up the search box. Enter a procedure code or description of the service.**

[For Medical Policy information, please access the BCBSMT Medical Policy Website](#)

Use this document to view details for a procedure code, including: 1) Drug Product Name - Brand (generic); 2) Reason for prior authorization where medical necessity review is required for both therapy and place of infusion (Infusion Site of Care) or for therapy only (Provider Administered Drug Therapy) and/or for Medical Oncology & Supportive Care and 3) Effective date for when prior authorization was implemented at BCBSMT (provider administered drug therapy or infusion site of care) or Carelon Medical Benefits Management (requests for oncology drugs that are supported by an oncology diagnosis).

Carelon Medical Benefits Management = Med Oncology & Supportive Care  
BCBSMT = Provider Administered Therapy Or Infusion Site Of Care

Send PA requests to BCBSMT for Provider Administered Therapy or Infusion Site of Care.

Send PA requests to Carelon for Medical Oncology and Supportive care unless drug requested has multiple indications. Carelon will only review requests for oncology drugs that are supported by an oncology diagnosis. Refer to the Update History / Prior Authorization Delegation Notes for details.

<b>Procedure Code</b>	<b>Service Category</b>	<b>Code Description</b>	<b>Managed By</b>	<b>Updates</b>
J0881	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Darbepoetin Alfa 1 Microgram (Non-Esrd Use)	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J0885	Infusion Site of Care, Medical Oncology & Supportive	Injection Epoetin Alfa (For Non-	Carelon or	Carelon will review requests for oncology drugs that are supported by
J1459	Infusion Site of Care, Medical Oncology & Supportive	Injection Immune Globulin (Privigen)	Carelon or	Carelon will review requests for oncology drugs that are supported by

J1551	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Cutaquig) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25.
J1552	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection, immune globulin (alyglo), 500 mg	Carelon or BCBSMT	Add Effective 04/01/2025. Add to Infusion Site of Care category 07/01/2025.
J1554	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Asceniv) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25.
J1555	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Cuvitru) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1556	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Bivigam) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1557	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Gammalex) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1558	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Xembify) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1559	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Hizentra) 100 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1561	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Gamunex-C/Gammaked) Non-Lyophilized (E. G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1566	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin Intravenous Lyophilized (E. G. Powder) Not Otherwise Specified 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1568	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Octagam) Intravenous Nonlyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.

J1569	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Gammagard Liquid) Non-Lyophilized (E. G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1572	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Flebogamma/Flebogamma Dif) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1575	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin/Hyaluronidase (Hyqvia) 100 Mg Immunoglobulin	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1576	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin (Panzyga) Intravenous Non-Lyophilized (E.G. Liquid) 500 Mg	Carelon or BCBSMT	Add to Provider Administered Drug Therapy 01/01/25. Add to Infusion Site of Care category 07/01/2025. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1599	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Immune Globulin Intravenous Non-Lyophilized (E.G. Liquid) Not Otherwise Specified 500 Mg	Carelon or BCBSMT	Add to Infusion Site of Care category 07/01/2025. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J1930	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Lanreotide 1 Mg	Carelon or BCBSMT	Add to Provider Administered Therapy 01/01/25. Add to Medical Oncology & Supportive Care 04/01/25. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J2353	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Octreotide Depot Form For Intramuscular Injection 1 Mg	Carelon or BCBSMT	Add to Provider Administered Therapy 01/01/25. Add to Medical Oncology & Supportive Care 04/01/25. Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
J9312	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS.
Q5106	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Epoetin Alfa-Epbx Biosimilar (Retacrit) (For Non-Esrd Use) 1000 Units	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25.
Q5115	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab-Abbs Biosimilar (Truxima) 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25.

Q5119	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab-Pvvr Biosimilar (Ruxience) 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25.
Q5123	Infusion Site of Care, Medical Oncology & Supportive Care, Provider Administered Drug Therapy	Injection Rituximab-Arrx Biosimilar (Riabni) 10 Mg	Carelon or BCBSMT	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis. If the drug requested is not associated with an oncology diagnosis, it will be reviewed by BCBS. Add to Provider Administered Drug Therapy 01/01/25.
90283	Infusion Site of Care, Provider Administered Drug Therapy	Immune Globulin (Igiv) Human For Intravenous Use	BCBSMT	Add to Infusion Site of Care category 07/01/2025.
90284	Infusion Site of Care, Provider Administered Drug Therapy	Immune Globulin (Scig) Human For Use In Subcutaneous Infusions 100 Mg Each	BCBSMT	Add to Infusion Site of Care category 07/01/2025.
J0129	Infusion Site of Care, Provider Administered Drug Therapy	Injection Abatacept 10 Mg (Code May Be Used For Medicare When Drug Administered Under The Direct Supervision Of A Physician Not For Use When Drug Is Self Administered)	BCBSMT	Prior Authorization required through BCBS.
J0180	Infusion Site of Care, Provider Administered Drug Therapy	Injection Agalsidase Beta 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J0219	Infusion Site of Care, Provider Administered Drug Therapy	Injection Avalglucosidase Alfa-Ngpt 4 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J0221	Infusion Site of Care, Provider Administered Drug Therapy	Injection Alglucosidase Alfa (Lumizyme) 10 Mg	BCBSMT	Prior Authorization required through BCBS.
J0222	Infusion Site of Care, Provider Administered Drug Therapy	Injection Patisiran 0.1 Mg	BCBSMT	Prior Authorization required through BCBS.
J0223	Infusion Site of Care, Provider Administered Drug Therapy	Injection, givosiran, 0.5 mg	BCBSMT	Add to "Provider Administered Drug Therapy" Category effective 01/01/2025
J0224	Infusion Site of Care, Provider Administered Drug Therapy	Injection, lumasiran, 0.5 mg	BCBSMT	Add to "Provider Administered Drug Therapy" Category effective 01/01/2025
J0485	Infusion Site of Care, Provider Administered Drug Therapy	Injection Belatacept 1 Mg	BCBSMT	Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS.
J0490	Infusion Site of Care, Provider Administered Drug Therapy	Injection Belimumab 10 Mg	BCBSMT	Prior Authorization required through BCBS.
J0491	Infusion Site of Care, Provider Administered Drug Therapy	Injection Anifrolumab-Fnia 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J0517	Infusion Site of Care, Provider Administered Drug Therapy	Injection Benralizumab 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J0584	Infusion Site of Care, Provider Administered Drug Therapy	Injection Burosumab-Twza 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J0598	Infusion Site of Care, Provider Administered Drug Therapy	Injection C-1 Esterase Inhibitor (Human) Cinryze 10 Units	BCBSMT	Prior Authorization required through BCBS.

J0638	Infusion Site of Care, Provider Administered Drug Therapy	Injection Canakinumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J0717	Infusion Site of Care, Provider Administered Drug Therapy	Injection Certolizumab Pegol 1 Mg (Code May Be Used For Medicare When Drug Administered Under The Direct Supervision Of A Physician Not For Use When Drug Is Self Administered)	BCBSMT	Prior Authorization required through BCBS.
J0791	Infusion Site of Care, Provider Administered Drug Therapy	Injection Crizanlizumab-Tmca 5 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J1290	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ecallantide 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J1299	Infusion Site of Care, Provider Administered Drug Therapy	Injection, eculizumab, 2 mg	BCBSMT	Add effective 07/01/2025
J1300	Infusion Site of Care, Provider Administered Drug Therapy	Injection Eculizumab 10 Mg	BCBSMT	Retire Effective 07/01/2025
J1301	Infusion Site of Care, Provider Administered Drug Therapy	Injection Edaravone 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J1302	Infusion Site of Care, Provider Administered Drug Therapy	Injection Sutimlimab-Jome 10 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J1303	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ravulizumab-Cwvz 10 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J1305	Infusion Site of Care, Provider Administered Drug Therapy	Injection Evinacumab-Dgnb 5Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J1306	Infusion Site of Care, Provider Administered Drug Therapy	Injection Inclisiran 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J1322	Infusion Site of Care, Provider Administered Drug Therapy	Injection Elosulfase Alfa 1Mg	BCBSMT	Prior Authorization required through BCBS.
J1458	Infusion Site of Care, Provider Administered Drug Therapy	Injection Galsulfase 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J1562	Infusion Site of Care, Provider Administered Drug Therapy	Injection Immune Globulin (Vivaglobin) 100 Mg	BCBSMT	Add to Infusion Site of Care category 07/01/2025.
J1602	Infusion Site of Care, Provider Administered Drug Therapy	Injection Golimumab 1 Mg For Intravenous Use	BCBSMT	Prior Authorization required through BCBS.
J1743	Infusion Site of Care, Provider Administered Drug Therapy	Injection Idursulfase 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J1745	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab Excludes Biosimilar 10 Mg	BCBSMT	Prior Authorization required through BCBS.
J1746	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ibalizumab-Uiyk 10 Mg	BCBSMT	Prior Authorization required through BCBS.
J1786	Infusion Site of Care, Provider Administered Drug Therapy	Injection Imiglucerase 10 Units	BCBSMT	Prior Authorization required through BCBS.
J1823	Infusion Site of Care, Provider Administered Drug Therapy	Injection Inebilizumab-Cdon 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.

J1931	Infusion Site of Care, Provider Administered Drug Therapy	Injection Laronidase 0.1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2182	Infusion Site of Care, Provider Administered Drug Therapy	Injection Mepolizumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2323	Infusion Site of Care, Provider Administered Drug Therapy	Injection Natalizumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2350	Infusion Site of Care, Provider Administered Drug Therapy	Injection Ocrelizumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2351	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq	BCBSMT	Add effective 07/01/2025
J2354	Infusion Site of Care, Provider Administered Drug Therapy	Injection Octreotide Non-Depot Form For Subcutaneous Or Intravenous Injection 25 Mcg	BCBSMT	Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS.
J2356	Infusion Site of Care, Provider Administered Drug Therapy	Injection Tezepelumab-Ekko 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J2357	Infusion Site of Care, Provider Administered Drug Therapy	Injection Omalizumab 5 Mg	BCBSMT	Prior Authorization required through BCBS.
J2507	Infusion Site of Care, Provider Administered Drug Therapy	Injection Pegloticase 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2786	Infusion Site of Care, Provider Administered Drug Therapy	Injection Reslizumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2796	Infusion Site of Care, Provider Administered Drug Therapy	Injection Romiplostim 10 Micrograms	BCBSMT	Add to Provider Administered Therapy 01/01/25. Retire Effective 04/01/25. Prior Authorization required through BCBS.
J2802	Infusion Site of Care, Provider Administered Drug Therapy	Injection, romiplostim, 1 microgram	BCBSMT	Add Effective 04/01/2025
J2840	Infusion Site of Care, Provider Administered Drug Therapy	Injection Sebelipase Alfa 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J3032	Infusion Site of Care, Provider Administered Drug Therapy	Injection Eptinezumab-Jjmr 1 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J3060	Infusion Site of Care, Provider Administered Drug Therapy	Injection Taliglucerase Alfa 10 Units	BCBSMT	Prior Authorization required through BCBS.
J3111	Infusion Site of Care, Provider Administered Drug Therapy	Injection Romosozumab-Aqqg 1 Mg	BCBSMT	Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS.
J3241	Infusion Site of Care, Provider Administered Drug Therapy	Injection Teprotumumab-Trbw 10 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
J3245	Infusion Site of Care, Provider Administered Drug Therapy	Injection Tildrakizumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J3262	Infusion Site of Care, Provider Administered Drug Therapy	Injection Tocilizumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J3358	Infusion Site of Care, Provider Administered Drug Therapy	Ustekinumab For Intravenous Injection 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J3380	Infusion Site of Care, Provider Administered Drug Therapy	Injection Vedolizumab Intravenous 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J3385	Infusion Site of Care, Provider Administered Drug Therapy	Injection Velaglucerase Alfa 100 Units	BCBSMT	Prior Authorization required through BCBS.

J3397	Infusion Site of Care, Provider Administered Drug Therapy	Injection Vestronidase Alfa-Vjbc 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J7183	Infusion Site of Care, Provider Administered Drug Therapy	Injection Von Willebrand Factor Complex (Human) Wilate 1 I.U. Vwf:Rco	BCBSMT	Add to Provider Administered Therapy 01/01/25. Prior Authorization required through BCBS.
J9332	Infusion Site of Care, Provider Administered Drug Therapy	Injection Efgartigimod Alfa-Fcab 2Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
Q5098	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg	BCBSMT	Add effective 10/1/2025
Q5099	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg	BCBSMT	Add effective 10/1/2025
Q5100	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg	BCBSMT	Add effective 10/1/2025
Q5103	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Dyyb Biosimilar (Inflixtra) 10 Mg	BCBSMT	Prior Authorization required through BCBS.
Q5104	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Abda Biosimilar (Renflexis) 10 Mg	BCBSMT	Prior Authorization required through BCBS.
Q5109	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Qbtx Biosimilar (Ixifi) 10 Mg	BCBSMT	Add to Provider Administered Therapy category 01/01/25. Prior Authorization required through BCBS.
Q5121	Infusion Site of Care, Provider Administered Drug Therapy	Injection Infliximab-Axxq Biosimilar (Avsola) 10 Mg	BCBSMT	Prior Authorization required through BCBS.
Q5133	Infusion Site of Care, Provider Administered Drug Therapy	Injection, Tocilizumab-Bavi (Tofidence), Biosimilar, 1 Mg	BCBSMT	Add Effective 01/01/2025. Add to Infusion Site of Care category 07/01/2025.
Q5134	Infusion Site of Care, Provider Administered Drug Therapy	Injection, Natalizumab-Sztn (Tyruko), Biosimilar, 1 Mg	BCBSMT	Add Effective 01/01/2025. Add to Infusion Site of Care category 07/01/2025.
Q5135	Infusion Site of Care, Provider Administered Drug Therapy	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg	BCBSMT	Add Effective 04/01/2025 to Provider Administered Drug Therapy. Add effective 07/01/2025 to Infusion Site of Care.
Q5138	Infusion Site of Care, Provider Administered Drug Therapy	ustekinumab-auub	BCBSMT	Add Effective 01/01/2025. Add to Infusion Site of Care category 07/01/2025.
Q5151	Infusion Site of Care, Provider Administered Drug Therapy	Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg	BCBSMT	Add effective 07/01/2025
Q5152	Infusion Site of Care, Provider Administered Drug Therapy	Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg	BCBSMT	Add effective 07/01/2025
Q9997	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg	BCBSMT	Add Effective 04/01/2025. Add to Infusion Site of Care category 07/01/2025.
Q9998	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-aekn (selarsdi), 1 mg	BCBSMT	Add Effective 04/01/2025. Add to Infusion Site of Care category 07/01/2025.
Q9999	Infusion Site of Care, Provider Administered Drug Therapy	Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg	BCBSMT	Add effective 07/01/2025
J0174	Infusion Site of Care, Provider Administered Drug Therapy	Injection, lecanemab-irmb, 1 mg	BCBSMT	Add effective 1/1/2026
Q5154	Infusion Site of Care, Provider Administered Drug Therapy	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg	BCBSMT	Add effective 1/1/2026
Q5156	Infusion Site of Care, Provider Administered Drug Therapy	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg	BCBSMT	Add effective 1/1/2026

C9169	Medical Oncology & Supportive Care	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram	Carelon	was to be added 01/01/2025, This code has since been replaced with code J9028
C9170	Medical Oncology & Supportive Care	Injection, tarlatamab-dlle, 1 mg	Carelon	was to be added 01/01/2025, This code has since been replaced with code J9026
C9399	Medical Oncology & Supportive Care	Unclassified Drugs Or Biologicals	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizuman-trjn). Add new drugs effective 10/01/24: Wyost/Jubbonti, Tevimbra, Anktiva, Hercessi, Imdeltra (all have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir [This drug to be reviewed under J9161 effective 7/1/25], Nypozi [This drug to be reviewed under Q5148 effective 7/1/25]; Add new drugs effective 04/01/25: Tecentriq Hybreza [This drug to be reviewed under J9024 effective 7/1/25], Vyloy [This drug to be reviewed under J1326 effective 10/1/25]; Add new drugs effective 07/01/25: zanidatamab-hrii [This drug to be reviewed under J9276 effective 10/1/25], zenocutuzumab-zbco [This drug to be reviewed under J9382 effective 10/1/25], cosibelimab-ipdl [This drug to be reviewed under J9275 effective 10/1/25], nivolumab hyaluronidase-nvhy [This drug to be reviewed under J9289 effective 10/1/25], datopotamab deruxtecan-dlnk [This drug to be reviewed under J9011 effective 01/1/26], denosumab-dssb [This drug to be reviewed under Q5159 effective 01/1/26]; Add new drugs effective 10/01/25: bevacizumab-nwgd, penpulimab-kcqx, denosumab-bmwo [This drug to be reviewed under Q5157 effective 01/1/26], denosumab-bnht [This drug to be reviewed under Q5158 effective 01/1/26]
J0641	Medical Oncology & Supportive Care	Injection Levoleucovorin Not Otherwise Specified 0.5 Mg	Carelon	Retire Effective 01/01/2025
J0642	Medical Oncology & Supportive Care	Injection Levoleucovorin (Khapzory) 0.5 Mg	Carelon	Prior Authorization required through Carelon.
J0870	Medical Oncology & Supportive Care	Imetelstat (Rytelo)	Carelon	Add Effective 01/01/2025
J0882	Medical Oncology & Supportive Care	Injection Darbepoetin Alfa 1 Microgram (For Esrd On Dialysis)	Carelon	Prior Authorization required through Carelon.
J0896	Medical Oncology & Supportive Care	Injection Luspatercept-Aamt 0.25 Mg	Carelon	Prior Authorization required through Carelon.
J0897	Medical Oncology & Supportive Care	Injection Denosumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J1323	Medical Oncology & Supportive Care	Injection Elranatamab-Bcmm 1 Mg	Carelon	-
J1326	Medical Oncology & Supportive Care	Vyloy (zolbetuximab-clzb)	Carelon	Add effective 10/1/2025
J1442	Medical Oncology & Supportive Care	Injection Filgrastim (G-Csf) Excludes Biosimilars 1 Microgram	Carelon	Prior Authorization required through Carelon.



J1447	Medical Oncology & Supportive Care	Injection Tbo-Filgrastim 1 Microgram	Carelon	Prior Authorization required through Carelon.
J1448	Medical Oncology & Supportive Care	Injection Trilaciclib 1Mg	Carelon	Prior Authorization required through Carelon.
J1449	Medical Oncology & Supportive Care	Injection Eflapegrastim-Xnst 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J2506	Medical Oncology & Supportive Care	Injection Pegfilgrastim Excludes Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.
J2820	Medical Oncology & Supportive Care	Injection Sargramostim (Gm-Csf) 50 Mcg	Carelon	Prior Authorization required through Carelon.
J2860	Medical Oncology & Supportive Care	Injection Siltuximab 10 Mg	Carelon	Prior Authorization required through Carelon.
J3055	Medical Oncology & Supportive Care	Injection Talquetamab-Tgvs 0.25 Mg	Carelon	-
J3263	Medical Oncology & Supportive Care	Loqtorzi (toripalimab-tpzi)	Carelon	-
J3490	Medical Oncology & Supportive Care	Unclassified Drugs	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizuman-trjn). Add new drugs effective 10/01/24: Wyost/Jubbonti, Tevimbra, Anktiva, Hercessi, lmdeltra (all have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir [This drug to be reviewed under J9161 effective 7/1/25], Nypozi [This drug to be reviewed under Q5148 effective 7/1/25]; Add new drugs effective 04/01/25: Tecentriq Hybreza [This drug to be reviewed under J9024 effective 7/1/25], Vyloy [This drug to be reviewed under J1326 effective 10/1/25]; Add new drugs effective 07/01/25: zanidatamab-hrii [This drug to be reviewed under J9276 effective 10/1/25], zenocutuzumab-zbco [This drug to be reviewed under J9382 effective 10/1/25], cosibelimab-ipdl [This drug to be reviewed under J9275 effective 10/1/25], nivolumab hyaluronidase-nvhy [This drug to be reviewed under J9289 effective 10/1/25], datopotamab deruxtecan-dlnk [This drug to be reviewed under J9011 effective 01/1/26], denosumab-dssb [This drug to be reviewed under Q5159 effective 01/1/26]; Add new drugs effective 10/01/25: bevacizumab-nwgd, penpulimab-kcqx, denosumab-bmwo [This drug to be reviewed under Q5157 effective 01/1/26], denosumab-bnht [This drug to be reviewed under Q5158 effective 01/1/26]

J3590	Medical Oncology & Supportive Care	Unclassified Biologics	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizuman-trjn). Add new drugs effective 10/01/24: Wyost/Jubbonti, Tevimbra, Anktiva, Hercessi, lmdeltra (all have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir [This drug to be reviewed under J9161 effective 7/1/25], Nypozi [This drug to be reviewed under Q5148 effective 7/1/25]; Add new drugs effective 04/01/25: Tecentriq Hybreza [This drug to be reviewed under J9024 effective 7/1/25], Vyloy [This drug to be reviewed under J1326 effective 10/1/25]; Add new drugs effective 07/01/25: zanidatamab-hrii [This drug to be reviewed under J9276 effective 10/1/25], zenocutuzumab-zbcx [This drug to be reviewed under J9382 effective 10/1/25], cosibelimab-ipdl [This drug to be reviewed under J9275 effective 10/1/25], nivolumab hyaluronidase-nvhy [This drug to be reviewed under J9289 effective 10/1/25], datopotamab deruxtecán-dlnk [This drug to be reviewed under J9011 effective 01/1/26], denosumab-dssb [This drug to be reviewed under Q5159 effective 01/1/26]; Add new drugs effective 10/01/25: bevacizumab-nwgd, penpulimab-kcqx, denosumab-bmwo [This drug to be reviewed under Q5157 effective 01/1/26], denosumab-bnht [This drug to be reviewed under Q5158 effective 01/1/26]
J9019	Medical Oncology & Supportive Care	Injection Asparaginase (Erwinaze) 1 000 lu	Carelon	Prior Authorization required through Carelon.
J9021	Medical Oncology & Supportive Care	Injection Asparaginase Recombinant (Rylaze) 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J9022	Medical Oncology & Supportive Care	Injection Atezolizumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9023	Medical Oncology & Supportive Care	Injection Avelumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9024	Medical Oncology & Supportive Care	Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)	Carelon	Add effective 07/01/2025
J9026	Medical Oncology & Supportive Care	Injection, tarlatamab-dlle, 1 mg	Carelon	Add Effective 01/01/2025
J9028	Medical Oncology & Supportive Care	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram	Carelon	Add Effective 01/01/2025
J9032	Medical Oncology & Supportive Care	Injection Belinostat 10 Mg	Carelon	Prior Authorization required through Carelon.
J9035	Medical Oncology & Supportive Care	Injection Bevacizumab 10 Mg	Carelon	Carelon will review requests for oncology drugs that are supported by an oncology diagnosis.
J9039	Medical Oncology & Supportive Care	Injection Blinatumomab 1 Microgram	Carelon	Prior Authorization required through Carelon.
J9042	Medical Oncology & Supportive Care	Injection Brentuximab Vedotin 1 Mg	Carelon	Prior Authorization required through Carelon.
J9043	Medical Oncology & Supportive Care	Injection Cabazitaxel 1 Mg	Carelon	Prior Authorization required through Carelon.
J9047	Medical Oncology & Supportive Care	Injection Carfilzomib 1 Mg	Carelon	Prior Authorization required through Carelon.

J9055	Medical Oncology & Supportive Care	Injection Cetuximab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9061	Medical Oncology & Supportive Care	Injection Amivantamab-Vmjw 2 Mg	Carelon	Prior Authorization required through Carelon.
J9063	Medical Oncology & Supportive Care	Injection Mirvetuximab Soravtansine-Gynx 1 Mg	Carelon	Prior Authorization required through Carelon.
J9064	Medical Oncology & Supportive Care	Injection Cabazitaxel (Sandoz) Not Therapeutically Equivalent To J9043 1 Mg	Carelon	—
J9118	Medical Oncology & Supportive Care	Injection Calaspargase Pegol-Mknl 10 Units	Carelon	Prior Authorization required through Carelon.
J9119	Medical Oncology & Supportive Care	Injection Cemiplimab-Rwlc 1 Mg	Carelon	Prior Authorization required through Carelon.
J9144	Medical Oncology & Supportive Care	Injection Daratumumab 10 Mg And Hyaluronidase-Fihj	Carelon	Prior Authorization required through Carelon.
J9145	Medical Oncology & Supportive Care	Injection Daratumumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9153	Medical Oncology & Supportive Care	Injection Liposomal 1 Mg Daunorubicin And 2.27 Mg Cytarabine	Carelon	Prior Authorization required through Carelon.
J9161	Medical Oncology & Supportive Care	Lymphir (denileukin diftitox-cxdl)	Carelon	Add effective 07/01/2025
J9173	Medical Oncology & Supportive Care	Injection Durvalumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9176	Medical Oncology & Supportive Care	Injection Elotuzumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J9177	Medical Oncology & Supportive Care	Injection Enfortumab Vedotin-Ejfv 0.25 Mg	Carelon	Prior Authorization required through Carelon.
J9179	Medical Oncology & Supportive Care	Injection Eribulin Mesylate 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J9203	Medical Oncology & Supportive Care	Injection Gemtuzumab Ozogamicin 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J9204	Medical Oncology & Supportive Care	Injection Mogamulizumab-Kpkc 1 Mg	Carelon	Prior Authorization required through Carelon.
J9205	Medical Oncology & Supportive Care	Injection Irinotecan Liposome 1 Mg	Carelon	Prior Authorization required through Carelon.
J9207	Medical Oncology & Supportive Care	Injection Ixabepilone 1 Mg	Carelon	Prior Authorization required through Carelon.
J9223	Medical Oncology & Supportive Care	Injection Lurbinectedin 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J9227	Medical Oncology & Supportive Care	Injection Isatuximab-lrfc 10 Mg	Carelon	Prior Authorization required through Carelon.
J9228	Medical Oncology & Supportive Care	Injection Ipilimumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J9229	Medical Oncology & Supportive Care	Injection Inotuzumab Ozogamicin 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J9258	Medical Oncology & Supportive Care	Injection Paclitaxel Protein-Bound Particles (Teva) Not Therapeutically Equivalent To J9264 1 Mg	Carelon	Retire Effective 01/01/2025
J9259	Medical Oncology & Supportive Care	Injection Paclitaxel Protein-Bound Particles (American Regent) Not Therapeutically Equivalent To J9264 1 Mg	Carelon	Retire Effective 04/01/2025
J9264	Medical Oncology & Supportive Care	Injection Paclitaxel Protein-Bound Particles 1 Mg	Carelon	Prior Authorization required through Carelon.

J9266	Medical Oncology & Supportive Care	Injection Pegaspargase Per Single Dose Vial	Carelon	Prior Authorization required through Carelon.
J9269	Medical Oncology & Supportive Care	Injection Tagraxofusp-Erzs 10 Micrograms	Carelon	Prior Authorization required through Carelon.
J9271	Medical Oncology & Supportive Care	Injection Pembrolizumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J9272	Medical Oncology & Supportive Care	Injection Dostarlimab-Gxly 10 Mg	Carelon	Prior Authorization required through Carelon.
J9273	Medical Oncology & Supportive Care	Injection Tisotumab Vedotin-Tftv 1 Mg	Carelon	Prior Authorization required through Carelon.
J9274	Medical Oncology & Supportive Care	Injection Tebentafusp-Tebn 1 Microgram	Carelon	Prior Authorization required through Carelon.
J9275	Medical Oncology & Supportive Care	Unloxcyt (cosibelimab-ipdl)	Carelon	Add effective 10/1/2025
J9276	Medical Oncology & Supportive Care	Ziihera (zanidatamab-hrii)	Carelon	Add effective 10/1/2025
J9281	Medical Oncology & Supportive Care	Mitomycin Pyelocalyceal Instillation 1 Mg	Carelon	Prior Authorization required through Carelon.
J9286	Medical Oncology & Supportive Care	Injection Glofitamab-Gxhm 2.5 Mg	Carelon	–
J9289	Medical Oncology & Supportive Care	Opdivo Qvantig (nivolumab hyaluronidase-nvhy)	Carelon	Add effective 10/1/2025
J9295	Medical Oncology & Supportive Care	Injection Necitumumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J9298	Medical Oncology & Supportive Care	Injection Nivolumab And Relatlimab-Rmbw 3 Mg/1 Mg	Carelon	Prior Authorization required through Carelon.
J9299	Medical Oncology & Supportive Care	Injection Nivolumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J9301	Medical Oncology & Supportive Care	Injection Obinutuzumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9302	Medical Oncology & Supportive Care	Injection Ofatumumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9303	Medical Oncology & Supportive Care	Injection Panitumumab 10 Mg	Carelon	Prior Authorization required through Carelon.
J9306	Medical Oncology & Supportive Care	Injection Pertuzumab 1 Mg	Carelon	Prior Authorization required through Carelon.
J9308	Medical Oncology & Supportive Care	Injection Ramucirumab 5 Mg	Carelon	Prior Authorization required through Carelon.
J9309	Medical Oncology & Supportive Care	Injection Polatuzumab Vedotin-Piiq 1 Mg	Carelon	Prior Authorization required through Carelon.
J9311	Medical Oncology & Supportive Care	Injection Rituximab 10 Mg And Hyaluronidase	Carelon	Prior Authorization required through Carelon.
J9316	Medical Oncology & Supportive Care	Injection Pertuzumab Trastuzumab And Hyaluronidase-Zzxf Per 10 Mg	Carelon	Prior Authorization required through Carelon.
J9317	Medical Oncology & Supportive Care	Injection Sacituzumab Govitecan-Hziy 2.5 Mg	Carelon	Prior Authorization required through Carelon.
J9321	Medical Oncology & Supportive Care	Injection Epcoritamab-Bysp 0.16 Mg	Carelon	–
J9325	Medical Oncology & Supportive Care	Injection Talimogene Laherparepvec Per 1 Million Plaque Forming Units	Carelon	Prior Authorization required through Carelon.
J9329	Medical Oncology & Supportive Care	Injection, tislelizumab-jsgr, 1mg	Carelon	Add Effective 01/01/2025
J9331	Medical Oncology & Supportive Care	Injection Sirolimus Protein-Bound Particles 1 Mg	Carelon	Prior Authorization required through Carelon.
J9345	Medical Oncology & Supportive Care	Injection Retifanimab-Dlwr 1 Mg	Carelon	Prior Authorization required through Carelon.

J9347	Medical Oncology & Supportive Care	Injection Tremelimumab-Actl 1 Mg	Carelon	Prior Authorization required through Carelon.
J9348	Medical Oncology & Supportive Care	Injection Naxitamab-Gqgk 1 Mg	Carelon	Prior Authorization required through Carelon.
J9349	Medical Oncology & Supportive Care	Injection Tafasitamab-Cxix 2 Mg	Carelon	Prior Authorization required through Carelon.
J9350	Medical Oncology & Supportive Care	Injection Mosunetuzumab-Axgb 1 Mg	Carelon	Prior Authorization required through Carelon.
J9352	Medical Oncology & Supportive Care	Injection Trabectedin 0.1 Mg	Carelon	Prior Authorization required through Carelon.
J9353	Medical Oncology & Supportive Care	Injection Margetuximab-Cmkb 5 Mg	Carelon	Prior Authorization required through Carelon.
J9354	Medical Oncology & Supportive Care	Injection Ado-Trastuzumab Emtansine 1 Mg	Carelon	Prior Authorization required through Carelon.
J9355	Medical Oncology & Supportive Care	Injection Trastuzumab Excludes Biosimilar 10 Mg	Carelon	Prior Authorization required through Carelon.
J9356	Medical Oncology & Supportive Care	Injection Trastuzumab 10 Mg And Hyaluronidase-Oysk	Carelon	Prior Authorization required through Carelon.
J9358	Medical Oncology & Supportive Care	Injection Fam-Trastuzumab Deruxtecan-Nxki 1 Mg	Carelon	Prior Authorization required through Carelon.
J9359	Medical Oncology & Supportive Care	Injection Loncastuximab Tesirine-Lpyl 0.075 Mg	Carelon	Prior Authorization required through Carelon.
J9361	Medical Oncology & Supportive Care	Ryzneuta (efbemalenograstim alfa-vuxw)	Carelon	–
J9380	Medical Oncology & Supportive Care	Injection Teclistamab-Cqyv 0.5 Mg	Carelon	Prior Authorization required through Carelon.
J9382	Medical Oncology & Supportive Care	Bizengri (zenocutuzumab-zbco)	Carelon	Add effective 10/1/2025

J9999	Medical Oncology & Supportive Care	Not Otherwise Classified Antineoplastic Drugs	Carelon	Code represents unclassified drugs or biologics. Prior Authorization required through Carelon. Unituxin (Dinutuximab). Add effective 07/01/24: Avzivi (bevacizuman-trjn). Add new drugs effective 10/01/24: Wyost/Jubbonti, Tevimbra, Anktiva, Hercessi, lmdeltra (all have specific codes effective 1/1/25); Add new drugs effective 01/01/25: Lymphir [This drug to be reviewed under J9161 effective 7/1/25], Nypozi [This drug to be reviewed under Q5148 effective 7/1/25]; Add new drugs effective 04/01/25: Tecentriq Hybreza [This drug to be reviewed under J9024 effective 7/1/25], Vyloy [This drug to be reviewed under J1326 effective 10/1/25]; Add new drugs effective 07/01/25: zanidatamab-hrii [This drug to be reviewed under J9276 effective 10/1/25], zenocutuzumab-zbco [This drug to be reviewed under J9382 effective 10/1/25], cosibelimab-ipdl [This drug to be reviewed under J9275 effective 10/1/25], nivolumab hyaluronidase-nvhy [This drug to be reviewed under J9289 effective 10/1/25], datopotamab deruxtecan-dlnk [This drug to be reviewed under J9011 effective 01/1/26], denosumab-dssb [This drug to be reviewed under Q5159 effective 01/1/26]; Add new drugs effective 10/01/25: bevacizumab-nwgd, penpulimab-kcqx, denosumab-bmwo [This drug to be reviewed under Q5157 effective 01/1/26], denosumab-bnht [This drug to be reviewed under Q5158 effective 01/1/26]
Q2043	Medical Oncology & Supportive Care	Sipuleucel-T Minimum Of 50 Million Autologous Cd54+ Cells Activated With Pap-Gm-Csf Including Leukapheresis And All Other Preparatory Procedures Per Infusion	Carelon	Prior Authorization required through Carelon.
Q2050	Medical Oncology & Supportive Care	Injection Doxorubicin Hydrochloride Liposomal Not Otherwise Specified 10Mg	Carelon	Prior Authorization required through Carelon.
Q4081	Medical Oncology & Supportive Care	Injection Epoetin Alfa 100 Units (For Esrd On Dialysis)	Carelon	Prior Authorization required through Carelon.
Q5101	Medical Oncology & Supportive Care	Injection Filgrastim-Sndz Biosimilar (Zarxio) 1 Microgram	Carelon	Prior Authorization required through Carelon.
Q5105	Medical Oncology & Supportive Care	Injection Epoetin Alfa-Epbx Biosimilar (Retacrit) (For Esrd On Dialysis) 100 Units	Carelon	Prior Authorization required through Carelon.
Q5107	Medical Oncology & Supportive Care	Injection Bevacizumab-Awwb Biosimilar (Mvasi) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5108	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Jmdb (Fulphila) Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.

Q5110	Medical Oncology & Supportive Care	Injection Filgrastim-Aafi Biosimilar (Nivestym) 1 Microgram	Carelon	Prior Authorization required through Carelon.
Q5111	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Cbqv (Udenyca) Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.
Q5112	Medical Oncology & Supportive Care	Injection Trastuzumab-Dttb Biosimilar (Ontruzant) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5113	Medical Oncology & Supportive Care	Injection Trastuzumab-Pkrb Biosimilar (Herzuma) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5114	Medical Oncology & Supportive Care	Injection Trastuzumab-Dkst Biosimilar (Ogivri) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5116	Medical Oncology & Supportive Care	Injection Trastuzumab-Qyyp Biosimilar (Trazimera) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5117	Medical Oncology & Supportive Care	Injection Trastuzumab-Anns Biosimilar (Kanjinti) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5118	Medical Oncology & Supportive Care	Injection Bevacizumab-Bvzr Biosimilar (Zirabev) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5120	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Bmez (Ziextenzo) Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.
Q5122	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Appf (Nyvepria) Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.
Q5125	Medical Oncology & Supportive Care	Injection Filgrastim-Ayow Biosimilar (Releuko) 1 Microgram	Carelon	Prior Authorization required through Carelon.
Q5126	Medical Oncology & Supportive Care	Injection Bevacizumab-Maly Biosimilar (Alymsys) 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5127	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Fpgk (Stimufend) Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.
Q5129	Medical Oncology & Supportive Care	Injection Bevacizumab-Adcd (Vegzelma) Biosimilar 10 Mg	Carelon	Prior Authorization required through Carelon.
Q5130	Medical Oncology & Supportive Care	Injection Pegfilgrastim-Pbbk (Fylnetra) Biosimilar 0.5 Mg	Carelon	Prior Authorization required through Carelon.
Q5136	Medical Oncology & Supportive Care	Injection, denosumab-bbdz (jubonti/wyost), biosimilar, 1 mg	Carelon	Add Effective 01/01/2025
Q5146	Medical Oncology & Supportive Care	Trastuzumab-strf (Hercessi)	Carelon	Add Effective 01/01/2025
Q5148	Medical Oncology & Supportive Care	Nypozi (filgrastim-txid)	Carelon	Add effective 07/01/2025
J9011	Medical Oncology & Supportive Care	Injection, datopotamab deruxtecán-dl	Carelon	Add effective 1/1/2026
Q5157	Medical Oncology & Supportive Care	Injection, denosumab-bmwo (stobock)	Carelon	Add effective 1/1/2026
Q5158	Medical Oncology & Supportive Care	Injection, denosumab-bnht (bomynta)	Carelon	Add effective 1/1/2026
Q5159	Medical Oncology & Supportive Care	Injection, denosumab-dssb (ospomyv)	Carelon	Add effective 1/1/2026
C9399, J3490, J3590, J9999	Medical Oncology & Supportive Care	Emrelis (telisotuzumab vedotin-tllv)	Carelon	Add effective 1/1/2026
C9399, J3490, J3590, J9999	Medical Oncology & Supportive Care	Zusduri (mitomycin)	Carelon	Add effective 1/1/2026
C9399, J3490, J3590, J9999	Medical Oncology & Supportive Care	Lynozyfic (linvoseltamab-gcpt)	Carelon	Add effective 1/1/2026

90378	Provider Administered Drug Therapy	Respiratory Syncytial Virus Monoclonal Antibody Recombinant For Intramuscular Use 50 Mg Each	BCBSMT	Retire Effective 10/1/2025. Prior Authorization required through BCBS.
J0172	Provider Administered Drug Therapy	Injection, Aducanumab-Avwa, 2 Mg	BCBSMT	Add Effective 01/01/2025, Retire Effective 04/01/2025
J0174	Provider Administered Drug Therapy	Injection, Lecanemab-Irmb, 1 Mg	BCBSMT	Add Effective 01/01/2025
J0175	Provider Administered Drug Therapy	donanemab-azbt	BCBSMT	Add Effective 01/01/2025
J0202	Provider Administered Drug Therapy	Injection Alemtuzumab 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J0218	Provider Administered Drug Therapy	Injection, Olipudase Alfa-Rpcp, 1 Mg	BCBSMT	Add Effective 01/01/2025
J0225	Provider Administered Drug Therapy	Injection, vutrisiran, 1 mg	BCBSMT	Add Effective 01/01/2025
J0567	Provider Administered Drug Therapy	Injection Cerliponase Alfa 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J0585	Provider Administered Drug Therapy	Injection Onabotulinumtoxina 1 Unit	BCBSMT	Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS.
J0586	Provider Administered Drug Therapy	Injection Abobotulinumtoxina 5 Units	BCBSMT	Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS.
J0587	Provider Administered Drug Therapy	Injection Rimabotulinumtoxina 100 Units	BCBSMT	Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS.
J0588	Provider Administered Drug Therapy	Injection Incobotulinumtoxin A 1 Unit	BCBSMT	Added to Infusion Site of Care 04/01/24. Removed from Infusion Site of Care 10/01/24. Prior Authorization required through BCBS.
J0589	Provider Administered Drug Therapy	Injection, Daxibotulinumtoxina-Lanm, 1 Unit	BCBSMT	Add Effective 01/01/2025
J0741	Provider Administered Drug Therapy	Injection Cabotegravir And Rilpivirine 2Mg/3Mg	BCBSMT	-
J0775	Provider Administered Drug Therapy	Injection Collagenase Clostridium Histolyticum 0.01 Mg	BCBSMT	Prior Authorization required through BCBS.
J0888	Provider Administered Drug Therapy	Injectin Epoetin Beta 1 Microgram (For Non Esrd Use)	BCBSMT	Prior Authorization required through BCBS.
J1203	Provider Administered Drug Therapy	Injection, Cipaglucosidase Alfa-Atga, 5 Mg	BCBSMT	Add Effective 01/01/2025
J1304	Provider Administered Drug Therapy	Injection, Tofersen, 1 Mg	BCBSMT	Add Effective 01/01/2025
J1307	Provider Administered Drug Therapy	Injection, crovalimab-akkz, 10 mg	BCBSMT	Add Effective 04/01/2025
J1411	Provider Administered Drug Therapy	Injection Etranacogene Dezaparovec-Drlb Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.
J1412	Provider Administered Drug Therapy	Injection Valoctocogene Roxaparovec-Rvox Per MI Containing Nominal 2 X 10 <sup>13</sup> Vector Genomes	BCBSMT	-



J1413	Provider Administered Drug Therapy	Injection Delandistrogene Moxeparovvec-Rokl Per Therapeutic Dose	BCBSMT	–
J1414	Provider Administered Drug Therapy	Injection, fidanacogene elaparovvec-dzkt, per therapeutic dose	BCBSMT	Retire Effective 10/1/2025. Add Effective 04/01/2025
J1426	Provider Administered Drug Therapy	Injection, Casimersen, 10 Mg	BCBSMT	Add Effective 01/01/2025
J1427	Provider Administered Drug Therapy	Injection, Viltolarsen, 10 Mg	BCBSMT	Add Effective 01/01/2025
J1428	Provider Administered Drug Therapy	Injection Eteplirsen 10 Mg	BCBSMT	Prior Authorization required through BCBS.
J1429	Provider Administered Drug Therapy	Injection, Golodirsen, 10 Mg	BCBSMT	Add Effective 01/01/2025
J1628	Provider Administered Drug Therapy	Injection, guselkumab, 1 mg	BCBSMT	Add Effective 04/01/2025
J1747	Provider Administered Drug Therapy	Injection, Spesolimab-Sbzo, 1 Mg	BCBSMT	Add Effective 01/01/2025
J1961	Provider Administered Drug Therapy	Injection Lenacapavir 1 Mg	BCBSMT	–
J2267	Provider Administered Drug Therapy	mirikizumab-mrkz	BCBSMT	Add Effective 01/01/2025
J2326	Provider Administered Drug Therapy	Injection Nusinersen 0.1 Mg	BCBSMT	Prior Authorization required through BCBS.
J2327	Provider Administered Drug Therapy	Injection, Risankizumab-Rzaa, Intravenous, 1 Mg	BCBSMT	Add Effective 01/01/2025
J2329	Provider Administered Drug Therapy	Injection, Ublituximab-Xiyy, 1Mg	BCBSMT	Add Effective 01/01/2025
J2508	Provider Administered Drug Therapy	Injection, Pegunigalsidase Alfa-lwxj, 1 Mg	BCBSMT	Add Effective 01/01/2025
J2562	Provider Administered Drug Therapy	Injection Plerixafor 1 Mg	BCBSMT	Retire Effective 10/1/2025. Prior Authorization required through BCBS.
J2941	Provider Administered Drug Therapy	Injection Somatropin 1 Mg	BCBSMT	Prior Authorization required through BCBS.
J3247	Provider Administered Drug Therapy	secukinumab (intravenous)	BCBSMT	Add Effective 01/01/2025
J3391	Provider Administered Drug Therapy	Injection, atidarsagene autotemcel, per treatment	BCBSMT	Add effective 10/1/2025
J3392	Provider Administered Drug Therapy	Injection, exagamglogene autotemcel, per treatment	BCBSMT	Add Effective 04/01/2025
J3393	Provider Administered Drug Therapy	Injection, betibeglogene autotemcel, per treatment	BCBSMT	Add Effective 01/01/2025
J3394	Provider Administered Drug Therapy	Injection, lovoitibeglogene autotemcel, per treatment	BCBSMT	Add Effective 01/01/2025
J3398	Provider Administered Drug Therapy	Injection Voretigene Neparovvec-Rzyl 1 Billion Vector Genomes	BCBSMT	Prior Authorization required through BCBS.
J3399	Provider Administered Drug Therapy	Injection Onasemnogene Abeparovvec-Xioi Per Treatment Up To 5X10^15 Vector Genomes	BCBSMT	Prior Authorization required through BCBS.
J3401	Provider Administered Drug Therapy	Beremagene Geperpavec-Svdt For Topical Administration Containing Nominal 5 X 10^9 Pfu/MI Vector Genomes Per 0.1 MI	BCBSMT	–
J9029	Provider Administered Drug Therapy	Intravesical Instillation Nadofaragene Firadenovvec-Vncg Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.

J9333	Provider Administered Drug Therapy	Injection, Rozanolizumab-Noli, 1 Mg	BCBSMT	Add Effective 01/01/2025
J9334	Provider Administered Drug Therapy	Injection, Efgartigimod Alfa, 2 Mg And Hyaluronidase-Qvfc	BCBSMT	Add Effective 01/01/2025
J9376	Provider Administered Drug Therapy	Injection, Pozelimab-Bbfg, 1 Mg	BCBSMT	Add Effective 01/01/2025
Q2041	Provider Administered Drug Therapy	Axicabtagene Ciloleucef Up To 200	BCBSMT	Prior Authorization required through BCBS.
Q2042	Provider Administered Drug Therapy	Tisagenlecleucef Up To 600 Million Car-Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.
Q2053	Provider Administered Drug Therapy	Brexucabtagene Autoleucef Up To 200 Million Autologous Anti-Cd19 Car Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.

Q2054	Provider Administered Drug Therapy	Lisocabtagene Maraleucel Up To 110 Million Autologous Anti-Cd19 Car-Positive Viable T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.
Q2055	Provider Administered Drug Therapy	Idecabtagene Vicleucel Up To 460 Million Autologous B-Cell Maturation Antigen (Bcma) Directed Car-Positive T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.
Q2056	Provider Administered Drug Therapy	Ciltacabtagene Autoleucel Up To 100 Million Autologous B-Cell Maturation Antigen (Bcma) Directed Car-Positive T Cells Including Leukapheresis And Dose Preparation Procedures Per Therapeutic Dose	BCBSMT	Prior Authorization required through BCBS.
Q2057	Provider Administered Drug Therapy	Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose	BCBSMT	Add effective 07/01/2025
Q2058	Provider Administered Drug Therapy	Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion	BCBSMT	Add effective 10/1/2025
Q5139	Provider Administered Drug Therapy	Injection, eculizumab-aeab (bkemv), biosimilar, 10 mg	BCBSMT	Add Effective 04/01/2025. Retire Effective 07/01/2025.
J0175	Provider Administered Drug Therapy	Injection, donanemab-azbt, 2 mg	BCBSMT	Add effective 1/1/2026
J0218	Provider Administered Drug Therapy	Injection, olipudase alfa-rpcp, 1 mg	BCBSMT	Add effective 1/1/2026
J0225	Provider Administered Drug Therapy	Injection, vutrisiran, 1 mg	BCBSMT	Add effective 1/1/2026
J0888	Provider Administered Drug Therapy	Injection, epoetin beta, 1 microgram,	BCBSMT	Add effective 1/1/2026
J2329	Provider Administered Drug Therapy	Injection, ublituximab-xiiy, 1mg	BCBSMT	Add effective 1/1/2026
J2508	Provider Administered Drug Therapy	Injection, pegunigalsidase alfa-iwxj, 1	BCBSMT	Add effective 1/1/2026
J3247	Provider Administered Drug Therapy	Injection, secukinumab, intravenous,	BCBSMT	Add effective 1/1/2026
J9333	Provider Administered Drug Therapy	Injection, rozanolixizumab-noli, 1 mg	BCBSMT	Add effective 1/1/2026
J9334	Provider Administered Drug Therapy	Injection, efgartigimod alfa, 2 mg and	BCBSMT	Add effective 1/1/2026
J9376	Provider Administered Drug Therapy	Injection, pozelimab-bbfg, 1 mg	BCBSMT	Add effective 1/1/2026

Important Notes:

CPT copyright 2024 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

Please note that checking eligibility and benefits and/or the fact that a service has received prior authorization is not a guarantee of payment. Benefits will be determined once a claim is received and will be based upon, among other things, the member's eligibility and the terms of the member's certificate of coverage applicable on the date services were rendered. The information provided does not constitute coding or legal advice. Physicians and other health care providers should use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment, and to submit claims using the most appropriate code(s) based upon the medical record documentation, coding guidelines and reference materials.

Availity is a trademark of Availity, LLC, a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSMT.

Carelon Medical Benefits Management is an independent company that has contracted with BCBSMT to provide utilization management services for members with coverage through BCBSMT.

BCBSMT makes no endorsement, representations or warranties regarding any products or services provided by third party vendors such as Availity or Carelon Medical Benefits Management. Please contact the vendor(s) directly for any questions regarding products or services offered.

Blue Cross and Blue Shield of Montana, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. ▪